Eli Lilly Ripe for Stock Split After Obesity Drug-Fueled Rally

Wall Street’s appetite for weight-loss drug stocks over the past four years has powered Eli Lilly & Co. to consistently trade above $1,000 per share. Now, some see the pharma giant’s stock as primed for a split.

To respect copyright, we link to the source rather than republishing the full text. Read the complete article on Bloomberg.